PROSCA/BLADDR 2020 | Immunotherapy in prostate cancer

Emmanuel Seront, MD, PhD, Jolimont Hospital, La Louvière, Belgium, discusses the use of immunotherapies in prostate cancer including ongoing studies evaluating immunotherapy and PARP inhibitors. Dr Seront highlights the importance of identifying patients that are more likely to respond to immunotherapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).